The BCL2 family consists of pro-apoptotic and anti-apoptotic proteins, and the balance between these regulates cell survival. This dynamic balance is often disrupted in cancers, including lymphomas, highlighting the relevance of targeting these proteins in treatment. In addition to tumorogenesis, aberrant expression of BCL2 family also leads to chemotherapy resistance due to compensatory mechanisms amongst the different proteins.
The aims of our research are:
Identifying combinations of BCL2 family proteins that efficiently reduce tumor burden without developing resistance to treatment.
Developing novel strategies for targeted drug delivery to the tumor. This will allow us to use combinations of BCL2 proteins and yet bypass the toxicities due to the ubiquitous use of these proteins in most cells in the body.